The drug pipelines of pharmaceutical companies like AstraZeneca are full of therapeutics being developed for personalized medicine, writes Frank Vinluan at MedCity News. AstraZeneca's Steve Labkoff says that 65 percent of the company's pipeline is personalized medicine. Vinluan adds that a common theme at the SAS Health Care and Life Sciences Executive Conference last week, where Labkoff was a speaker, was that "big data healthcare information is on its way to consumers" and that it will extend beyond medicine to insurance.
"Analysis of patient data from [Blue Cross Blue Shield North Carolina] will enable the company to develop plans tailored to customers," Vinluan writes, adding that big data is "already helping to develop pharmaceuticals personalized to patients. And soon their healthcare plans will become personalized, too."